UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects

Clinical therapeutics, 2011-09, Vol.33 (9), p.1142-1149

2011

Volltextzugriff (PDF)

Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Serum and Cytosol of Tumor Tissue from Patients with Primary Breast Cancer

Clinical cancer research, 2002-05, Vol.8 (5), p.1132-1141

2002

Volltextzugriff (PDF)

High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival

Breast cancer research and treatment, 2003-07, Vol.80 (1), p.15-21

2003

Volltextzugriff (PDF)

Abstract A3: A first-in-man, phase I, dose escalation study of TB-403, a monoclonal antibody directed against PlGF, in healthy male subjects

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A3-A3

2009

Volltextzugriff (PDF)

A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer

Acta oncologica, 2008, Vol.47 (4), p.618-632

2008

Volltextzugriff (PDF)

Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity

Blood, 2007-11, Vol.110 (11), p.312-312

2007

Volltextzugriff (PDF)

Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer

Acta oncologica, 2007, Vol.46 (6), p.782-791

2007

Volltextzugriff (PDF)

Soluble urokinase plasminogen activator receptor measurements: Influence of sample handling

The International journal of biological markers, 2001-10, Vol.16 (4), p.233-239

2001

Volltextzugriff (PDF)

Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration

The International journal of biological markers, 2005-04, Vol.20 (2), p.93-102

2005

Volltextzugriff (PDF)

Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders

European journal of haematology, 2003-11, Vol.71 (5), p.377-384

2003

Volltextzugriff (PDF)

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)

APMIS : acta pathologica, microbiologica et immunologica Scandinavica, 2006-10, Vol.114 (10), p.675-681

2006

Volltextzugriff (PDF)

Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera

European journal of haematology, 2002-07, Vol.69 (1), p.43-49

2002

Volltextzugriff (PDF)

Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism

European journal of haematology, 2003-10, Vol.71 (4), p.276-282

2003

Volltextzugriff (PDF)

1 – 13 von 13

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(13)

Sprache

Englisch
(13)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(10)
Life Sciences & Biomedicine
(10)
Science & Technology
(10)
Adult
(9)
Middle Aged
(9)
Biological And Medical Sciences
(8)
Female
(8)
Medical Sciences
(8)
Aged
(7)
Aged, 80 And Over
(6)
Receptors, Urokinase Plasminogen Activator
(6)
Oncology
(5)
Prognosis
(5)
Supar
(5)
Receptors, Cell Surface - Blood
(4)
Enzyme-Linked Immunosorbent Assay
(3)
Hematologic And Hematopoietic Diseases
(3)
Hematology
(3)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(3)
Male
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects

Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Serum and Cytosol of Tumor Tissue from Patients with Primary Breast Cancer

High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival

Abstract A3: A first-in-man, phase I, dose escalation study of TB-403, a monoclonal antibody directed against PlGF, in healthy male subjects

A comparison among HER2, TP53, PAI-1, angiogenesis, and proliferation activity as prognostic variables in tumours from 408 patients diagnosed with early breast cancer

Phase I Clinical Trial of a Novel, Long-Acting Antithrombotic Drug: A Human Monoclonal Antibody Partially Inhibiting FVIII Activity

Lack of association between level of Plasminogen Activator Inhibitor-1 and estimates of tumor angiogenesis in early breast cancer

Soluble urokinase plasminogen activator receptor measurements: Influence of sample handling

Preoperative plasma soluble urokinase plasminogen activator receptor as a prognostic marker in rectal cancer patients. An EORTC-Receptor and Biomarker Group collaboration

Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders

Prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) in Danish patients with recurrent epithelial ovarian cancer (REOC)

Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera

Collagen metabolism and enzymes of the urokinase plasminogen activator system in chronic myeloproliferative disorders: correlation between plasma-soluble urokinase plasminogen activator receptor and serum markers for collagen metabolism

Suchergebnisse filtern